Pharmakonzern: Roche trimmt Forschung auf Effizienz und peilt 20 neue Medikamente an
Bis 2030 will Roche bis zu 20 neue Wirkstoffe auf den Markt bringen – mit einem Spitzenumsatzpotenzial von teilweise mehr als drei Milliarden Franken pro Wirkstoff.
Pharmakonzern Roche announced plans to streamline its research efforts and focus on developing new medications, particularly for obesity, at its Pharma Investor Day in London. The company aims to allocate approximately two billion Swiss francs of cost savings towards more profitable projects by the end of 2026. Additionally, Roche intends to reduce the time required to develop new medications by around 19 months.
Early successes include a higher success rate in phase-III studies, which rose to over 80 percent in the current year, up from 65 percent in 2025. Roche is targeting the lucrative market for cardiovascular and metabolic disorders, with three obesity candidates - Petrelintide, CT-996, and Enicepatide - advancing to the final stage of clinical development.
In response, the company is reevaluating its pipeline and halting the development of a less promising obesity medication in phase II. Roche will also initiate further phase-III studies in eye care and lung cancer, as well as submit new applications for drug approvals targeting multiple sclerosis and eye diseases.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
